{
    "nct_id": "NCT03374995",
    "official_title": "Pilot Study: KeraStat Cream for Radiation Dermatitis",
    "inclusion_criteria": "* Diagnosis of breast cancer, received chemotherapy, and scheduled to receive 4 to 6 weeks of radiation therapy (radiation protocol of 42 Gy+)\n* Area to be irradiated representing 1-10% of total body surface area (TBSA)\n* Able and willing to sign protocol consent form\n* Able and willing to document symptoms and treatment details as often as needed, not to exceed daily notes\n* Able and willing to have photographs of the affected area taken regularly\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years\nMust have maximum age of 70 Years",
    "exclusion_criteria": "* Women who are pregnant, lactating/nursing or plan to become pregnant\n* Previous radiation therapy to the area to be treated with radiation therapy\n* Receiving palliative radiation therapy\n* Unhealed or infected surgical sites in the irradiation area\n* Patients undergoing cytotoxic chemotherapy or concurrent Herceptin as part of overall treatment plan (tamoxifen/aromatase inhibitor allowed)\n* Use of oral corticosteroids or topical corticosteroids in the irradiation area\n* Use of Erbitux\n* Autoimmune disease\n* Skin disease in target irradiation area\n* Smoker\n* Known allergy to the standard of care or ingredients in KeraStat Cream",
    "miscellaneous_criteria": ""
}